Acorda Therapeutics Inc (ACORQ)
OTCMKTS: ACORQ · Delayed Price · USD
0.400
0.00 (0.00%)
Apr 15, 2024, 12:00 AM EDT - Market open

Company Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.

The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.

It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.

The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Acorda Therapeutics Inc
Country United States
Founded 1995
IPO Date Feb 10, 2006
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 102
CEO Ron Cohen

Contact Details

Address:
Two Blue Hill Plaza
Pearl River, New York 10965
United States
Phone 914-347-4300

Stock Details

Ticker Symbol ACORQ
Exchange OTCMKTS
Fiscal Year January - December
CIK Code 0001008848
CUSIP Number 00484M106
ISIN Number US00484M6012
Employer ID 13-3831168
SIC Code 2836

Key Executives

Name Position
Dr. Ron Cohen M.D. Founder, Chief Executive Officer, President and Director
Michael A. Gesser M.B.A. Chief Financial Officer
Kerry M. Clem Chief Commercial Officer
Robert Morales Interim Principal Accounting Officer, Principal Financial Officer, Vice President of Finance and Controller
Felicia Vonella Vice President of Investor Relations
Neil S. Belloff Esq. General Counsel and Corporate Secretary
Tierney Saccavino Executive Vice President of Corporate Communications
Denise J. Duca Executive Vice President of Human Resources
Andrew Mayer J.D. Senior Vice President
Sofia Ali Senior Vice President of Operations and Strategic Planning

Latest SEC Filings

Date Type Title
Apr 4, 2024 8-K Current Report
Apr 2, 2024 8-K Current Report
Apr 1, 2024 10-K Annual Report
Mar 13, 2024 8-K Current Report
Jan 11, 2024 8-K Current Report
Dec 1, 2023 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report
Aug 9, 2023 10-Q Quarterly Report
Aug 8, 2023 8-K Current Report